Effect of isotretinoin therapy on natural killer cell activity in patients with xeroderma pigmentosum

British Journal of Dermatology

Volumn 138, Issue 2, 1998, Pages 236-241

  Anolik, J H ^a   Di Giovanna, J J ^a   Gaspari, A A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DNA REPAIR; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; NATURAL KILLER CELL; PHOTOSENSITIVITY; PRIORITY JOURNAL; SCHOOL CHILD; SKIN CANCER; XERODERMA PIGMENTOSUM;

ADOLESCENT; ADULT; CELLS, CULTURED; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-2; ISOTRETINOIN; KERATOLYTIC AGENTS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; XERODERMA PIGMENTOSUM;

EID: 0031917432     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02067.x     Document Type: Article

References (29)

1. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Arch Dermatol 1987; 123: 241-50.
2. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. Arch Dermatol 1994; 130: 1018-21.
3. Levy DD, Saijo M. Tanaka K, Kraemer KH. Expression of a transfected DNA repair gene (XPA) in xeroderma pigmentosum group A cells restores normal DNA repair and mutagenesis of UV-treated plasmids. Carcinogen 1995; 16: 1557-63.
4. Dupuy JM, Lafforet D. A defect of cellular immunity in xeroderma pigmentosum. Clin Immunol Immunopathol 1974; 3: 52-8.
5. Wysenbeck AJ, Weiss H, Duczyminerokahana M et al. Immunologic alterations in xeroderma pigmentosum patients. Cancer 1986; 58: 219-21.
6. Salamon T, Stojakovic M, Bogdanovic B. Delayed hypersensitivity in xeroderma pigmentosum. Arch Dermatol Forsch 1975; 251: 277-80.
7. Norris PG, Limb GA, Hamblin AS et al. Immune function, mutant frequency, and cancer risk in the DNA repair defective genodermatoses xeroderma pigmentosum. Cockayne's syndrome, and trichothiodystrophy. J Invest Dermatol 1990; 94: 94-100.
8. Norris PG, Limb GA, Hamblin AS, Hawk JLM. Impairment of natural killer cell activity in xeroderma pigmentosum. N Engl J Med 1988; 319: 1668-9.
9. Mariani K, Facchini A, Honorati MC et al. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy. Clin Exp Immunol 1992; 88: 376-83.
10. Gaspari AA, Fleisher TA, Kraemer KH. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest 1993; 92: 1135-42.
11. Kraemer KH, DiGiovanna JJ, Moshell AN et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1989; 318: 1633-7.
12. Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19: 715-18.
13. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol 1992; 27: 534-7.
14. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-64.
15. Lippman SM, Kessler JF, Meyskins FL. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987; 71: 391-405.
16. Duncan RC, Knapp RG. Introductory Biostatistics for the Health Sciences (Clinton Miller M, ed.). New York: John Wiley & Sons, 1977.
17. McKerrow KJ, Mackie RM, Lesko MJ, Pearson C. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol 1988; 119: 313-20.
18. Ermin O, Ashby J, Rhodes J. Inhibition of antibody-dependent cellular cytotoxicity and natural cytotoxicity by retinoic acid. Int Arch Allergy Appl Immunol 1984; 75: 2-7.
19. Abb J, Abb H, Deinhardt F. Effect of retinoic acid on the spontaneous and IFN-induced activity of human natural killer cells. Int J Cancer 1982; 30: 307-10.
20. Pigatto PD, Bersani L, Colotta F et al. Effect of retinoids on natural killer cell activity. Arch Dermatol Res 1986; 278: 507-9.
21. Goldfarb RH, Herberman RB. Natural killer cell reactivity: regulatory interactions among phorbol ester, interferon, cholera toxin, and retinoic acid. J Immunol 1981; 126: 2129-35.
22. de The H, Marchio A, Tiollais P, Dejean A. Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J 1989; 8: 429-33.
23. Jetten AM. Multi-stage program of differentiation in human epidermal keratinocytes: regulation by retinoids. J Invest Dermatol 1990; 95: 44-6S.
24. Levin AA, Sturzenbecker LJ. Kazmer S. 9-cis retinoic acid stereo-isomer binds and activates the nuclear receptor RXRα. Nature 1992; 355: 359-61.
25. Felli MP, Vacca A, Meco D et al. Retinoic acid-induced downregulation of the interleukin-2 promoter via cis-regulatory sequences containing an octamer motif. Mol Cell Biol 1991; 11: 4771-8.
26. Blalock JE, Gifford GE. Retinoic acid (vitamin A acid) induced transcriptional control of interferon production. Proc Natl Acad Sci USA 1977; 74: 5382-6.
27. Cornell RC, Greenway HT, Tucker SB et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
28. Moore DM, Kalvakolanu DV, Lippman SM et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994; 31 (Suppl. 5): 31-7.
29. Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. 13-cis-retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5.